1-20 of 48
Sort by
News

January 2024 Data Stream

Published: 2024
Abstract
January 2024
View News titled, January 2024 Data Stream
News

ASH Offers Resources to Support Professional Development in the New Year

Published: 2024
Abstract
January 2024
View News titled, ASH Offers Resources to Support Professional Development in the New Year
News

At-Home Hemoglobin Test Kit for Anemia Receives Approval

Published: 2024
Abstract
January 2024
View News titled, At-Home Hemoglobin Test Kit for Anemia Receives Approval
News

Patients With More Severe SCD Symptoms Are Generally More Accepting of Gene Therapy

Deborah Levenson
Published: 2024
Abstract
January 2024
View News titled, Patients With More Severe SCD Symptoms Are Generally More Accepting of Gene Therapy
News

Isa-KRd Quadruplet Yields “Unprecedented” MRD Negativity in Newly Diagnosed High-Risk MM

Leah Lawrence
Published: 2024
Abstract
January 2024
View News titled, Isa-KRd Quadruplet Yields “Unprecedented” MRD Negativity in Newly Diagnosed High-Risk MM
News

Health Disparities Persist in Hemophilia Life Expectancy

Lara C. Pullen, PhD
Published: 2024
Abstract
January 2024
View News titled, Health Disparities Persist in Hemophilia Life Expectancy
News

Small-Volume Blood Collection Tubes Can Reduce Transfusions in Intensive Care

Leah Lawrence
Published: 2024
Abstract
January 2024
View News titled, Small-Volume Blood Collection Tubes Can Reduce Transfusions in Intensive Care
News

Serum TARC Levels Increased Years Prior to Hodgkin Lymphoma Diagnosis

Leah Lawrence
Published: 2024
Abstract
January 2024
View News titled, Serum TARC Levels Increased Years Prior to Hodgkin Lymphoma Diagnosis
News

What second-line therapies would you recommend for Rosai-Dorfman disease following a modest partial response to prednisone?

Published: 2024
Abstract
January 2024
View News titled, What second-line therapies would you recommend for Rosai-Dorfman disease following a modest partial response to prednisone?
News

You Make the Call: What second-line therapies would you recommend for Rosai-Dorfman disease following a modest partial response to prednisone?

Published: 2024
Abstract
January 2024
View News titled, You Make the Call: What second-line therapies would you recommend for Rosai-Dorfman disease following a modest partial response to prednisone?
News

To Kill a MOC(kingbird)

Published: 2024
Abstract
January 2024
View News titled, To Kill a MOC(kingbird)
News

CHMP Supports Pfizer’s R/R MM Treatment

Published: 2023
Abstract
January 2024
View News titled, CHMP Supports Pfizer’s R/R MM Treatment
News

FDA Places Partial Hold on T-Cell Lymphomas Treatment Studies

Published: 2023
Abstract
January 2024
View News titled, FDA Places Partial Hold on T-Cell Lymphomas Treatment Studies
News

AbbVie’s R/R MM Treatment Combination Fails to Improve PFS

Published: 2023
Abstract
January 2024
View News titled, AbbVie’s R/R MM Treatment Combination Fails to Improve PFS
News

FDA Proposes New Rule to Improve Safety for Laboratory-Developed Tests

Published: 2023
Abstract
January 2024
View News titled, FDA Proposes New Rule to Improve Safety for Laboratory-Developed Tests
News

Hung Up on Art: Louis Aledort, MD

Linda Kossoff
Published: 2023
Abstract
January 2024 Louis Aledort, MD, MACP, talks about how his fervent appreciation of art led to an extensive at-home collection of museum-worthy pieces.
View News titled, Hung Up on Art: Louis Aledort, MD
News

When a Cure Isn’t an Option

Mary Ellen Schneider
Published: 2023
Abstract
January 2024 Hematologists can work with mental health professionals to support patients living with chronic cancer.
View News titled, When a Cure Isn’t an Option
News

Science, Greed, Ambition Led to Development of BTK Inhibitors

Andrew Cowan, MD
Published: 2023
Abstract
January 2024
View News titled, Science, Greed, Ambition Led to Development of BTK Inhibitors
News

Teclistamab Shows Strong Results in Patients With High-Risk Smoldering Myeloma

Thomas R. Collins
Published: 2023
Abstract
January 2024
View News titled, Teclistamab Shows Strong Results in Patients With High-Risk Smoldering Myeloma
News

Dosing Recommendations After Elranatamab Interruptions Decrease CRS Events in R/R MM

Khylia Marshall
Published: 2023
Abstract
January 2024
View News titled, Dosing Recommendations After Elranatamab Interruptions Decrease CRS Events in R/R MM